TargetBeta
DMD
dystrophin · also BMD, DXS142, DXS164, DXS206 · Zinc fingers ZZ-type
2 programs in company-led studies act on DMD, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| delandistrogene moxeparvovecrule | Sarepta Therapeutics | – | phase 4 | 11 running | – | ChEMBL |
| delpacibart zotadirsen | Novartis | – | phase 3 | 32 running | – | the company's pipeline |
Conditions their studies are in
- Muscular Dystrophy, Duchenne, 2 programs
- Myotonic Dystrophy, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 30, 2027delpacibart zotadirsen · Novartis · phase 3 · NCT06244082
- Aug 31, 2027delandistrogene moxeparvovec · Sarepta Therapeutics · phase 4 · NCT07542314
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.